1 / 38

Acute Meningitis Reşat ÖZARAS, MD , Prof. Infection Dept. rozaras@yahoo

Acute Meningitis Reşat ÖZARAS, MD , Prof. Infection Dept. rozaras@yahoo.com. CNS INFECTIONS Overview. Life-threatening problems with High mortality High morbidity Presentation acute, subacute, chronic

flynn
Télécharger la présentation

Acute Meningitis Reşat ÖZARAS, MD , Prof. Infection Dept. rozaras@yahoo

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Acute Meningitis Reşat ÖZARAS, MD, Prof. Infection Dept. rozaras@yahoo.com

  2. CNS INFECTIONSOverview • Life-threatening problems with • High mortality • High morbidity • Presentation • acute, • subacute, • chronic • Clinical findings determined by anatomic site(s) of involvement, infecting pathogen, and host response

  3. ACUTE CNS INFECTIONS 1. Bacterial meningitis 2. Meningoencephalitis 3. Brain abscess 4. Subdural empyema 5. Epidural abscess 6. Septic venous sinus thrombophlebitis

  4. Routes of Entry • Hematogenous • Neighboring focus • Anatomic defect • congenital • traumatic • surgical • Intraneural pathways

  5. Acute Meningitis

  6. THE PATIENT WITH ACUTE CNS INFECTIONOverall Goals in Management 1. To promptly recognize the patient with an acute CNS infection syndrome 2. To rapidly initiate appropriate empiric therapy 3. To rapidly and specifically identify the etiologic agent, adjusting therapies as indicated 4. To optimize management of complicating features

  7. APPROACH TO THE PATIENT WITH SUSPECTED MENINGITIS Decision-Making Within the First 30 Minutes Clinical Assessment Mode of presentation Acute (< 24 hrs) Subacute (< 7 days) Chronic (> 4 wks) Historical/physical exam clues Clinical status of the patient Integrity of host defenses

  8. Clinical Features • Fever • Headache • Nuchal rigidity • Altered mental status • Photophobia • Non-specific symptoms/signs • Focal neurological signs • Seizures • Specific clinical stigmata according to etiological agent • Children / elderly

  9. rushemergencymedicine.com

  10. CSF STUDIES • Color/Clarity • Cell counts/WBC diff • Chemistries (protein, glucose) • Stains/Smears (Gram) • Cultures (routine) • +/- Antigen screens

  11. APPROACH TO THE PATIENT WITHSUSPECTED MENINGITIS Decision-Making at 1-2 Hours CSF Analysis CSF smears/stains CSF antigen screens CSF “profile”

  12. CSF SMEARS & STAINS • GmS + in 60-90% of pts with untreated bacterial meningitis • With prior ATB Rx, positivity of GmS decreases to 40-60% • REMEMBER: + GmS = Heavy organism burden & worse prognosis

  13. CSF ANTIGEN SCREENS • Bacterial antigen screens detect S. pneumoniae, N. meningitidis, Hib; + in 50-100% of pts (esp. useful in pts with prior ATB Rx) • Crypto antigen screen detects C. neoformans; + in 90-95% of pts with crypto meningitis • Should NOT be a ordered routinely

  14. CEREBROSPINAL FLUID PROFILES Neutrophilic/Low glucose (purulent) Lymphocytic/Normal glucose Lymphocytic/Low glucose

  15. APPROACH TO THE PATIENT WITH SUSPECTED MENINGITIS Decision-Making at 24-48 hours CSF Culture Results Culture positive  Adjust therapy based upon specific organism and sensitivities Culture negative  Evaluate for “aseptic” meningitis syndrome

  16. TO LP OR NOT TO LP • Single most impt diagnostic test • Mandatory, esp if bacterial meningitis suspected • If LP contraindicated, obtain BCs (+ in 50-60%), then begin empirical Rx

  17. THE PATIENT WITH SUSPECTEDCNS INFECTIONContraindications to LP Absolute: Skin infection over site Papilledema, focal neuro signs, ↓MS Relative: Increased ICP without papilledema Suspicion of mass lesion Spinal cord tumor Spinal epidural abscess Bleeding diathesis or ↓ plts

  18. CNS INFECTIONSCT • Over-employed diagnostic modality  Leads to unnecessary delays in Rx & added cost • Rarely indicated in pt with suspected acute meningitis • Mandatory in pt with possible focal infection • Increased sensitivity with contrast enhancement

  19. THE THERAPY OF MENINGITISDesirable Antimicrobic Properties 1. Activity vs suspected pathogen(s) [preferably cidal] 2. Adequate CSF diffusion 3. Acceptable risk of toxicity

  20. Good Diffusion Penicillins 3rd& 4th Gen Cephs Chloramphenicol Rifampin TSX Poor Diffusion Early Gen Cephs Clindamycin AMGs Tetracyclines Macrolides THE THERAPY OF MENINGITISCNS Penetration

  21. Bacterial MeningitisImportant Changes in Epidemiology • Marked decline in the occurrence of Hib • ↑’ing incidence of S. pneumo (50+% of cases in US) • Shift from peds disease to adult disease • ↑’ing incidence of ATB-resistant organisms, esp. S. pneumo • PCN resistance ~ 35% (15-20% high level) • Ceph resistance 15-20% (5-10% high level)

  22. Predisposing Factor Age 0-4 wk 4-12 wk 3 mo to 18 yr 18-50 yr >50 yr Common Bacterial Pathogens Streptococcus agalactiae, Escherichia coli, Listeria monocytogenes, Klebsiella pneumoniae, Enterococcus spp., Salmonella spp. S. agalactiae, E. coli, L. monocytogenes, Haemophilus influenzae, Streptococcus pneumoniae, Neisseria meningitidis H. influenzae, N. meningitidis, S. pneumoniae S. pneumoniae, N. meningitidis S. pneumoniae, N. meningitidis, L. monocytogenes, aerobic gram-negative bacilli COMMON BACTERIAL PATHOGENS BASED ON PREDISPOSING FACTOR IN PATIENTS WITH MENINGITIS

  23. Etiology - in Adults • S. pneumoniae 30-50% • N. meningitidis 10-35% • H. influenzae 1-3% • G -ve bacilli 1-10% • Listeria species 5% • Streptococci 5% • Staphylococci 5-15%

  24. EMPIRIC THERAPY OF MENINGITIS IN THE ADULT Clinical SettingLikely PathogensTherapy Community-acquired S. pneumoniae Ceftriaxone N. meningitidis 2 gm q12h [Listeria] + [H. influenzae] Ampicillin 2 gm q4h Closed head trauma S. pneumoniae Pen G 3-4 mu q4h Streptococci + Vancomycin 1-2 gm q12h

  25. Role of Steroids • The addition of anti-inflammatory agents has been attempted as an adjuvant in the treatment of meningitis • Early administration of corticosteroids for pediatric meningitis has shown no survival advantage, but there is a reduction in the incidence of severe neurologic complications and deafness • Less bilateral deafness late neurological sequelae in controls compared to children treated with steroids

  26. Community-acquired S. pneumoniae Ceftriaxone N. meningitidis2 gm q12h [Listeria] + [H. influenzae] Ampicillin 2 gm q4h + Dexamethasone

  27. Enteroviruses Polioviruses Coxsackieviruses Echoviruses Togaviruses Eastern equine Western equine Venezuelan equine St. Louis Powasson California West Nile Herpesviruses Herpes simplex Varicella-zoster Epstein Barr Cytomegalovirus Myxo/paramyxoviruses Influenza/parainfluenzae Mumps Measles Miscellaneous Adenoviruses LCM Rabies HIV VIRAL MENINGITIS/ENCEPHALITIS

  28. NONVIRAL CAUSES OF ENCEPHALOMYELITIS Rocky Mountain spotted fever Acanthamoeba Typhus Toxoplasma Mycoplasma Plasmodium falciparum Brucellosis Trypanosomiasis Subacute bacterial endocarditis Whipple’s disease Syphilis (meningovascular) Behcet’s disease Relapsing fever Vasculitis Lyme disease Leptospirosis Tuberculosis Cryptococcus Histoplasma Naegleria

  29. Cryptococcosis

  30. Toxoplasmosis

More Related